Hikma R&D Investor Spotlight Series

Summary by AI BETAClose X

Hikma Pharmaceuticals PLC has announced an R&D Investor Spotlight Series comprising three educational seminars focused on its R&D strategy and capabilities, with the company aspiring to invest between 5% and 6% of revenue in R&D going forward to strengthen its global pipeline. The seminars, scheduled for October 20th, November 24th, and December 16th, will cover Group R&D and specific product areas including Respiratory, Nasal, Semi-Solids and Liquids, Solid Orals, and Injectables, though no new financial or trading information will be disclosed.

Disclaimer*

UK 100

Latest directors dealings